Rabby Wallet has addressed a vulnerability that could occur in the 10-minute auto-lock setting and released an update on August 11. This vulnerability was a limited flaw that only occurred when a connection to a malicious website was made while the auto-lock timer was set to 10 minutes. Rabby Wallet stated that the team completed the fix after confirming the vulnerability and has distributed the update. The mobile application was not affected by this vulnerability. For the flaw to be exploited, users needed to connect their wallet to a malicious website and set the auto-lock timer to 10 minutes. Other auto-lock settings were not impacted. Auto-lock is a security feature that restricts access when a user has not interacted with the wallet for a certain period. Rabby Wallet is a browser wallet that supports Ethereum and EVM-compatible networks, providing features such as risk scanning before transactions and displaying balance changes before signing. The latest version in the Chrome Web Store is listed as 0.94.2. This announcement informs users about the fix for a vulnerability that could occur under limited conditions rather than a widespread breach. Rabby Wallet has stated that it has not yet found any instances of this vulnerability being exploited in real-world environments. Users can check whether the extension has been updated and verify their auto-lock settings.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.


















Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.











